

## **ONLINE-SUPPLEMENTARY APPENDIX**

### **Duration of the efficacy of omalizumab after treatment discontinuation in “real life” severe asthma**

María del Carmen Vennera MD<sup>1,2</sup>, Carlos Sabadell MD<sup>3</sup>, César Picado MD, FERS<sup>1,2</sup> and the Spanish Omalizumab Registry.

1.- Department of Pneumology and Respiratory Allergy, Hospital Clinic. IDIBAPS. Universitat de Barcelona. Barcelona, Spain.

2.- Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES). Spain.

3.- Department of Pneumology. Hospital de Figueres. Figueres. Girona, Spain.

### **Statistical Analysis**

For comparisons between visits in continuous variables, parametric (paired Student's t-test), and non-parametric tests (Wilcoxon) were used when appropriate. For comparisons between groups, parametric (Student's t-test or ANOVA) and non-parametric tests (Mann–Whitney), were used in continuous variables, and chi-square test or Fisher's exact were used in categorical variables. A level of statistical significance of 0.05 was applied in all the statistical tests.

**TABLE E1: Clinical variables and lung function test before initiation of omalizumab therapy. Comparison between Success and Failure groups**

	Success		Failure		p-values
	n	%	n	%	
<b>Prick test</b>	<b>37</b>	<b>100.0</b>	<b>12</b>	<b>100.0</b>	<b>0.3154</b>
Positive	32	86.5	12	100.0	
Negative	5	13.5	0	0.0	
<b>Chronic Rhinosinusitis (CRS)</b>	<b>37</b>	<b>100.0</b>	<b>12</b>	<b>100.0</b>	<b>0.1391</b>
Yes	24	64.9	11	91.7	
No	13	35.1	1	8.3	
<b>CRS with Nasal Polyps (CRSwNP)</b>	<b>37</b>	<b>100.0</b>	<b>12</b>	<b>100.0</b>	<b>0.1151</b>
Yes	15	40.5	8	66.7	
No	22	59.5	4	33.3	
<b>Non-steroidal anti-inflammatory drugs (NSAIDs) intolerance</b>	<b>37</b>	<b>100.0</b>	<b>12</b>	<b>100.0</b>	<b>0.0942</b>
Yes	11	29.7	7	58.3	
No	26	70.3	5	41.7	
	Success		Failure		P-values
	Mean (DT) Median (25 <sup>TH</sup> -75 <sup>TH</sup> )		Mean (DT) Median (25 <sup>TH</sup> -75 <sup>TH</sup> )		
<b>Age (years)*</b>	56.3±11.8		53.8±9.4		<b>0.4958</b>
<b>BMI (kg/m<sup>2</sup>)*</b>	28.2±6.4		25.9±3.9		<b>0.2591</b>
<b>Years of asthma</b>	24.0±15.1		26.1±16.1		<b>0.6191</b>
<b>Asthma control test (ACT)</b>	15.1 ± 5.5 15.0 (10.0-20.0)		12.4 ± 5.2 13.0 (10.0-15.0)		<b>0.1574</b>
<b>Exacerbation Rate (ER)</b>	4.4 ± 3.3 3.0 (2.0-6.0)		4.8 ± 3.9 3.5 (1.5-9.5)		<b>0.8613</b>
<b>FEV1 (%)</b>	63.6 ± 20.3 61.8 (51.7-70.3)		68.3 ± 19.4 70.7 (59.6-81.6)		<b>0.4904</b>

Note \*: Age and BMI at the cessation (VC) of treatment with omalizumab

**Asthma treatment before initiation of omalizumab therapy (PT) and prior to cessation (VC). Comparison between Success and Failure groups.**

**TABLE E2: Continuous oral corticosteroid therapy**

VISIT	Oral Corticosteroids	Groups n (%)		Total	P
		Success	Failure		
Pre-treatment Visit (PT)	No	27 (73%)	12 (100%)	39 (79,6%)	0,0926
	Yes	10 (27%)	0 (0%)	10 (20,4%)	
Treatment cessation Visit (VC)	No	35 (94,6%)	12 (100%)	47 (95,9%)	1,0000
	Yes	2 (5,4%)	0 (0%)	2 (4,1%)	

**TABLE E3: Long-acting  $\beta$ 2 agonists (Salmeterol, Formoterol)**

VISIT	LABAs	Groups n (%)		Groups n (%)	P
		Success	Success		
Pre-treatment (PT)	No	2 (5,4%)	1 (8,3%)	3 (6,1%)	1,0000
	Yes	35 (94,6%)	11 (91,7%)	46 (93,9%)	
Treatment cessation (VC)	No	10 (27%)	2 (16,7%)	12 (24,5%)	0,7034
	Yes	27 (73%)	10 (83,3%)	37 (75,5%)	

**TABLE E4: Inhaled corticosteroids (budesonide equivalent doses in  $\mu$ g)**

Groups	Pre-treatment visit (PT)	Cessation visit (VC)
Success	1875.68 $\pm$ 1306.18	1130.00 $\pm$ 731.16
Failure	1600.00 $\pm$ 614.96	1048.00 $\pm$ 434.02

Note: Each cell shows the mean  $\pm$  standard deviation (SD). There were no statistically significant differences either at PT or VC